


Intellectual Property advocacy in the fields of:

- IP Infrastructure
- IP Valuation
- M & A
- IP Policy
- Technology Transfer
- Innovation Research
- Patent Law
- Licensing
- Data Management
- Copyright
- Collaborations
- Balance for Rights & Obligations



TechEx.in, Venture Center is excited to announce PREPARATORY COURSE for PATENT AGENT EXAMINATION (PAE) aimed at budding Patent Agent aspirants to help them clear PAE 2025!

Organized by



Supported by

Preparatory Course for PATENT AGENT EXAMINATION


Start Date: 5 November 2024 | End Date: 7 December 2024 | Time: 16:00 - 17:30 pm daily

Who can benefit:


- IP Managers in Industry
- SME Owners
- IT Scientists, Technologists, Executives, Engineers
- Students and Legal Professionals (science/tech degree) preparing for the Patent Agents Exam

Join the course to understand:

- Key provisions of the Patent Act 1970 and associated rules
- Patent procedures and prosecution at the Patent Office
- Provisions relating to International Application under the Patents Act 1970 & Rules
- Drafting Patent Specifications and documents for patent prosecution
- Solving previous years' papers of Patent Agents Examination
- Mock Exam and Interview for practice
- Certificate of participation issued by TechEx.in at Venture Center




Register Now!



Expert Guidance by
Dr. Gopakumar Nair

Lead Faculty -
Dr. Srividya Ravi




Course Fees: INR 5000/- | Limited Seats Available

Technical Queries: Archana Joshi | archana@ipface.org | Registration Queries: Kirti Dubey | kirti.dubey@ipface.org

HAPPY DIWALI & Prosperous New Year

 **Course Dates: 5 November - 7 December 2024**

 **Time: 4:00 pm - 5:30 pm**

About the preparatory course -

- Patent Agent Examination is a formal assessment that qualifies individuals to act as Patent Agents, allowing them to represent, draft for and help inventors in protecting their inventions.
- The one-month long course is designed to equip attendees with essential knowledge and skills to clear the Patent Agent Exam.

The course will be concluded by the expert guidance from Dr. Gopakumar Nair.

 **Register Now:**

<https://tinyurl.com/PrepCourse-PAE2025>

 **Last Date to Register: 4th November 2024, Monday.**

For queries:

 Technical: Archana Joshi | archana@ipface.org

 Registration: Kirti Dubey | kirti.dubey@ipface.org | 8956457041

 **Note: Registration and Payment are Mandatory. Sessions will be conducted on Zoom.**

**ONESOURCE, THE STRIDES GROUP'S SPEC
PHARM CDMO, RECEIVES EQUITY
COMMITMENTS OF INR 8,010 MN (USD 95 MN)
FROM MARQUEE INVESTORS AT A PRE-MONEY
EQUITY VALUATION OF USD 1.65 BN.**

Delivering Strides' shareholders an embedded value of INR 663 per share for Strides' holding in OneSource, representing a ~82% premium over the previous embedded value of INR 364 per share as per the Scheme of Arrangement announced earlier in September'23.

The fundraise is being led by HBM Healthcare Investments and associated investors, with the additional participation inter alia from WhiteOak Capital, Param Capital, Motilal Oswal, Enam Holdings and SBI Life Insurance Co Ltd.

Bangalore, India, October 16, 2024 - StridesPharma Science Limited (Strides) today announced that it's associate company,

OneSource Specialty Pharma Limited (formerly known as Stelis Biopharma Limited), Group's Specialty Pharma CDMO, has received confirmed commitments for fundraising of INR 8,010 mn (~USD 95 mn) from marquee domestic and foreign institutional investors and family offices, in the pre-listing round.

The share subscription agreements are being executed at a pre-money equity value of USD 1.65 bn, delivering to Strides' shareholders an embedded value of INR 663 per share of Strides' holding in OneSource representing an ~82% premium over the previous embedded value of INR 364 per share as per the Scheme of Arrangement announced earlier in September'23.

The strong interest from leading investors reflects growing confidence in our capabilities and the immense potential of the CDMO sector emerging out of India.

This fundraise is in line with the Scheme of Arrangement announced in September'23 and the investment is subject to customary closing conditions, including receipt of necessary regulatory approvals.

DSK Legal acted as the legal counsel for OneSource and Transaction Square was the advisor to the Scheme.

Background: On 25th September'23, Strides announced the creation of OneSource, India's first specialty pharma pure-play CDMO player by integrating Stelis' Biologics CDMO, SteriScience's Complex Injectables, and Strides' Soft Gelatine businesses in a single entity by way of Scheme of Arrangement.

As part of the Scheme, Strides shareholders are to receive 1 share of OneSource for every 2 shares of Strides

(Swap Ratio of 1:2).

OneSource is in the process of seeking final approval for the Scheme from NCLT, Mumbai Bench, to thereafter achieve the listing of equity shares by March'25, upon receipt of regulatory approvals.

DRUG PRICE CONTROL MUST BENEFIT THE PATIENTS

Ever since the Drugs Price Control Order (DPCO) came into force, the emphasis has been on reducing the prices of medicines to benefit the consumers.

Successive governments have excessively abused the DPCO, as a popular measure to canvass votes. The IDPL (Indian Drugs and

Pharmaceuticals Ltd) established in 1961, flourished in providing a leadership role in abundant availability of bulk drugs (APIs) and generic medicines at affordable prices for many years (nearly 20 years). Unfortunately, sadly, and most deplorably, the elected representatives of the Government, who become Health Ministers and Ministers of C&F (Chemicals and Fertilizers) under whom IDPL was functioning over the years, especially during election times, repeatedly used to announce reduction of prices of IDPL medicines, for gaining popularity, so much so, eventually, IDPL had to close down. The Crown Jewel of IDPL, the Hyderabad plant has now been converted to NIPER (National Institute of Pharmaceutical Education and Research). The Hyderabad, Rishikesh, and Gurgaon plants of IDPL, which had closed down, are being revived and brought back to life, restarting production of formulations. This initiative from the Modi Government is especially welcome to benefit consumers' high affordable access to generic life sciences medicines.

The Modi Government, in its third term, has been adopting pragmatic policies to promote the health of Indian Pharmaceutical Companies, which have a large international presence and contribute overwhelmingly to India's export trade. The NPPA (National Pharmaceutical Pricing Authority) has increased the price of certain essential medicines to increase production and improve market availability. By making these drugs affordable to manufacture, asthma, tuberculosis, and mental health-related medicinal formulations, which were in short supply in the market due to the cost of products

exceeding MRP (selling price), will now be available to needy patients. This is a timely welcome by the government.

Availability of affordable medicines can only be facilitated by not only making the medicines affordable to patients, but also by making it affordable for the manufacturer to produce them without incurring a loss. A pragmatic approach, as recently done by the government, is essential to strike a balance.

THALASSAEMIA, TB, ASTHMA DRUGS BECOME MORE AVAILABLE AND ACCESSIBLE WITH PRICE REVISION MAKING DRUGS AFFORDABLE TO MANUFACTURE

NEW DELHI: Prices of several essential drugs used to treat conditions such as asthma, glaucoma, thalassaemia, tuberculosis and mental health disorders, are expected to rise, as govt has approved a 50% increase in their ceiling price.

Regarding the reason behind the decision, the govt, in a statement on Monday, said, "The National Pharmaceutical Pricing Authority (NPPA) has been receiving applications from manufacturers for an upward revision of prices, citing various reasons such as increased costs of active pharmaceutical ingredients, rising production costs, changes in exchange rates, and more, which have resulted in the unviability of sustainable production and marketing of drugs. Companies have also applied for the discontinuation of some formulations due to their unviability."

invoking extraordinary powers under Para 19 of DPCO-2013, and in larger public interest, NPPA has approved increase in the ceiling prices of 11 scheduled formulations of eight drugs by 50% of their current ceiling prices," it added.

The eight drug formulations for which ceiling prices have been revised are: Benzyl Penicillin 10 lakh IU injection; Atropine injection 06.mg/ml; Streptomycin powder for injection 750mg and 1000mg; Salbutamol tablet 2mg and 4mg and respirator solution 5mg/ml; Pilocarpine 2% drops; Cefadroxil tablet 500mg, Desferrioxamine 500mg for injection; and Lithium tablets 300mg.

Most of these drugs are low-cost and generally used as first-line treatment crucial to public health programmes. "The price revision is unlikely to impact patients significantly as most of these drugs are available for free to them at govt hospitals and through public health



initiatives meant to provide free treatment," said a senior

official.

NPPA had exercised its powers in 2019 and 2021 to increase the prices of 21 and nine formulations, respectively, by 50% to ensure continued availability of essential drugs for the public.

The Above news article can be accessed through the

Link provided:

<https://timesofindia.indiatimes.com/india/thalassaemia-tb-asthma-drug-prices-set-to-rise/articleshow/114228066.cms>